Poseida Therapeutics (NASDAQ:PSTX) Upgraded by Zacks Investment Research to Hold

Poseida Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Poseida Therapeutics Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

View More Poseida Therapeutics (NASDAQ:PSTX) Upgraded by Zacks Investment Research to Hold